


Additional Files

The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis

Ping Tan, M.D. ^{a, b, *}, Shiyou Wei, M.D. ^{c, *}, Lu Yang, Ph.D ^{a, b, *}, Zhuang Tang, M.D. ^{a, b}, Dehong Cao, M.D. ^{a, b}, Liangren Liu, Ph.D ^{a, b}, Junhao Lei, M.D. ^{a, b}, Yu Fan, M.D. ^{a, b}, Liang Gao, M.D. ^{a, b}, Qiang Wei, M.D ^{a, b}

Additional file 1. Trial Identification, Inclusion, and Exclusion.




Additional file 2. Studies evaluating the association between long-term statins use and BCR risk of prostate cancer.

Study	HR [#]	95%CI	Recurrence cases	Definition of long-term statin use
Song et al. 2015 (Korea)	0.64	0.40-1.05	NR [*]	>36 months
ishak-Howard et al.2014(US)	0.932	0.53-1.63	NR	>5 years
Kontraros et al.2013(Greece)	1.63	1.02-2.60	NR	>2 years
Geybels et al.2013(US)	1.06	0.67-1.67	22	>5 years
Mondul et al.2011(US)	0.77	0.41-1.42	NR	>1 years
Chao et al.2013(US)	0.96	0.64-1.46	NR	>500 days
Chao et al.2013(US)	1.04	0.67-1.64	NR	>500 days

*NR, not report; #HR, Hazard Ratio; 95%CI, 95% confidence intervals.

Additional file 3. The meta-analysis of effect of long-term statins use on BCR risk of prostate cancer.



Additional file 4. Funnel plot for publication bias of 22 studies analysing BCR risk of prostate cancer.

